Login to Your Account

Evolus seeks $75M to bring back aesthetic market entry

By Michael Fitzhug
Staff Writer

Wednesday, January 10, 2018

SAN FRANCISCO – Little more than five minutes' drive from Botox-maker Allergan plc's chief research center in Irvine, Calif., Evolus Inc. is prepping for a $75 million IPO that, if successful, could create new competition for the botulinum toxin king. The company is advancing PrabotulinumtoxinA, also known as DWP-450, an injectable 900 kilodalton botulinum toxin type A complex licensed from South Korea's Daewoong Pharmaceuticals Co. Ltd.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription